Swedish-based CDMO Recipharm announced at CPHI that it is “expanding its pharmaceutical development capabilities through targeted investments and the integration of cutting-edge technologies”. This, it said, will bolster services at both early- and late- stage development, giving it fully integrated services that cover the whole life cycle of a molecule. These additions comprise:

French CDMO EuroAPI announces today that it has completed and secured the financing of its ongoing Focus-27 strategic plan. The agreements comprise:

* An agreement with EuroAPI’s banking syndicate on a new secured €451 million revolving credit facility, refinancing the existing revolving facility to mature in February 2029

* An investment by Sanofi of €200 million in a perpetual deeply subordinated hybrid bond, which EuroAPI said that will give it “additional financial flexibility” to deliver Focus-27

CDMO SK Pharmteco has announced plans to invest $260 million in a new small molecule and peptide facility in Sejong, South Korea, the fifth in its home country and the cornerstone of its global manufacturing network. This is scheduled to begin operations in late 2026, creating over 300 jobs.

Cambrex’s Snapdragon Chemistry subsidiary has developed a new liquid-phase peptide synthesis (LPPS) technology that uses traditional API batch reactors and continuous flow, obviating the dependency on specialised, solid-phase reactors. It also “materially reduces solvent demand and the need for excess reagents compared to standard solid-state peptide synthesis (SPPS) processes”.

Karsten Smet, CEO of ACI Group, looks at ways the pharmaceutical and agrochemical industries can adapt to changing times

Italian CDMO and API producer Olon Group has acquired its compatriot HuvePharma Italia, which makes APIs and advanced intermediates via chemical synthesis, from the Huvepharma EOOD group. This is part of Olon’s strategy of growth, consolidation and expansion, both internally and through acquisitions

Barentz International has acquired distributors in two different regions in short order. The acquisition of Insuqui in Paraguay followed a few weeks after that of the Anshul Life Sciences Group in India. Terms were not disclosed in either deal and the existing management teams will remain in place.